Table 1:

Clinical and imaging data of patients with low-grade gliomas demonstrating increased contrast enhancement

Clinical InformationNo. of Patients
Sex
    Female33 (34.4%)
    Male63 (65.6%)
Age range (yr)
    20–3935 (36.5%)
    40–5947 (49.0%)
    Older than 6014 (14.5%)
KPS
    ≥9074 (77.1%)
    ≤8022 (22.9%)
Histologic subtype
    Diffuse astrocytoma30 (31.3%)
    Oligoastrocytoma27 (28.1%)
    Oligodendroglioma39 (40.6%)
IDH1 mutation
    Wild-type7 (7.3%)
    Mutant61 (63.5%)
    Not available28 (29.2%)
Baseline residual tumor
    Yes81 (84.4%)
    No15 (15.6%)
Disease duration
    <2 years10 (10.4%)
    2–5 years35 (36.5%)
    5–10 years25 (26.0%)
    >10 years26 (27.1%)
Adjuvant therapy
    RT75 (78.1%)
    Carmustine implant9 (9.4%)
    Temozolomide16 (16.7%)
Post-RT duration
    <6 months2 (2.7%)
    6–12 months5 (6.7%)
    12–24 months9 (12%)
    >24 months59 (78.6%)
Whole tumor size
    <4 cm217 (17.7%)
    4–16 cm245 (46.9%)
    >16 cm234 (35.4%)
Contrast enhancement size
    <4 cm237 (38.5%)
    4–16 cm236 (37.5%)
    >16 cm223 (24.0%)
Tumor grade
    II42 (43.8%)
    III27 (28.1%
    IV27 (28.1%)
  • Note:—RT indicates radiation therapy; KPS, Karnofsky Performance Scale.